PETV Overview

PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Company’s lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a body’s cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.

Wall Street analysts forecast PETV stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PETV is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

PetVivo Holdings Inc revenue for the last quarter amounts to 200.72K USD, decreased -3.20

PetVivo Holdings Inc. EPS for the last quarter amounts to -0.11 USD, decreased -60.71

PetVivo Holdings Inc (PETV) has 25 emplpoyees as of March 10 2026.

Today PETV has the market capitalization of 0.00 USD.